Elsevier

Ophthalmology

Volume 100, Issue 4, April 1993, Pages 550-555
Ophthalmology

Visual Prognosis in Giant Cell Arteritis

https://doi.org/10.1016/S0161-6420(93)31608-8Get rights and content

Purpose: The visual prognosis in giant cell arteritis (GCA) was evaluated over a 5year period.

Methods: The authors reviewed the records of all patients with a diagnosis of GCA established at the Mayo Clinic over a 5-year period regarding visual status. Follow-up data for these patients were obtained 5 years later.

Results: Of the 245 patients studied, 34 (14%) permanently lost vision because of GCA. In 32 of these patients, the visual deficit developed before glucocorticoid therapy for GCA was begun; in the 2 other patients, the visual loss occurred after the diagnosis was made and therapy was started. Visual loss progressed in three patients after initiation of oral glucocorticoids, and in five other patients vision improved. After 5 years, the probability of loss of vision developing after initiating oral glucocorticoid treatment was determined to be 1 % (Kaplan-Meier technique), and the probability of additional loss was 13% in patients with GCA who had a visual deficit at the time therapy was begun.

Conclusion: The development or progression of visual loss was rare after the initiation of glucocorticoid therapy.

References (28)

  • L Fernandez-Herlihy

    Temporal arteritis: clinical aids to diagnosis

    J Rheumatol

    (1988)
  • C Hugod et al.

    Temporal arteritis-progressive affection of vision during high-level corticosteroid therapy. A case report

    Acta Med Scand

    (1979)
  • KL Faarvang et al.

    Giant cell arteritis: loss of vision during corticosteroid therapy

    J Intern Med

    (1989)
  • JF Cullen

    Temporal arteritis. Occurrence of ocular complications 7 years after diagnosis

    Br J Ophthalmol

    (1972)
  • Cited by (332)

    • High risk and low prevalence diseases: Giant cell arteritis

      2022, American Journal of Emergency Medicine
      Citation Excerpt :

      Treatment with steroids should be initiated as soon as GCA is suspected [33,60-62]. Management should not be delayed while awaiting TAB, as delayed treatment could result in acute ischemic optic neuropathy and permanent vision loss [63]. For patients with high suspicion of GCA and symptoms of vision lossor involvement of large vessels (such as aortitis), administration of methylprednisolone 1000 mg IV once per day, for 3 days, is recommended [33,39,61].

    View all citing articles on Scopus

    Supported in part by NIH grant EY08039 (William M. Bourne), an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York, and by Mayo Foundation, Rochester, Minnesota.

    View full text